ad image

Company Info

Catalent

Catalent

CDMO / Supply Chain Logistics

Overview

Catalent Pharma Solutions is a global leader in development solutions and advanced delivery technologies, providing worldwide clinical and commercial supply capabilities for drugs, biologics, and consumer health and beauty products. Catalent has been serving the pharmaceutical industry for more than 80 years, with expertise in bringing customer products to market faster, enhancing product performance and ensuring reliable product supply. In 2017, Catalent acquired Cook Pharma as part of a strategic expansion of its biologics business.
Catalent
Contributions
21 Contributions1 / 2
Catalent

Catalent to Acquire RheinCell Therapeutics, Strengthening a Path Towards Industrialization of Induced Pluripotent Stem Cell-based Therapies

Catalent

PA909Jun 25, 2021
Planning for Success, Addressing Quality Early for Gene Therapies
Gene Therapy

Planning for Success, Addressing Quality Early for Gene Therapies

Maribeth Donovan Janke, Ph.D.

Catalent

PAO-05-21-CL-02May 21, 2021
Innovative Strategies to Maintain Product Integrity in Biologic and Biosimilar Clinical Studies
Clinical Trial Logistics

Innovative Strategies to Maintain Product Integrity in Biologic and Biosimilar Clinical Studies

Mark Woolf

Catalent

PAO-03-21-CL-06Mar 22, 2021
Phase-Appropriate CMC Activities Facilitate the Transition from Early Development through Commercialization
Chemistry, Manufacturing, and Controls

Phase-Appropriate CMC Activities Facilitate the Transition from Early Development through Commercialization

Matthew Rota; Lisa Caralli; Jim Spavins

Catalent

PAO-01-21-CL-05Feb 05, 2021
Allogeneic T Cell Therapies: Efficient Commercial Manufacturing Readiness using “Manufacturing by Design” Methodology
Cell Therapy

Allogeneic T Cell Therapies: Efficient Commercial Manufacturing Readiness using “Manufacturing by Design” Methodology

Catalent

PAO-12-20-CL-01Dec 16, 2020
How COVID-19 Is Reshaping Vaccine Development: Innovations in Vaccine Technology and Partnerships
COVID-19 vaccine

How COVID-19 Is Reshaping Vaccine Development: Innovations in Vaccine Technology and Partnerships

Graham Brearley, Ph.D.; Jared Davis, Ph.D.

Catalent

PAP-Q4-20-CL-007Dec 09, 2020
Getting Your Biologic to Clinic Faster and More Efficiently
Clinical Supply

Getting Your Biologic to Clinic Faster and More Efficiently

Ann McMahon; Pamela Barton

Catalent

PAP-Q3-20-CL-011Sep 29, 2020
Catalent
COVID-19 Vaccine

Catalent Signs Agreement with AstraZeneca to Expand Manufacturing Support for COVID-19 Vaccine AZD1222

Catalent

PR-M08-20-NI-41Aug 26, 2020
Catalent
Expansion

Catalent Adds Potent Manufacturing Capabilities at its Buenos Aires, Argentina Site

Catalent

PR-M08-20-NI-13Aug 07, 2020
Catalent
COVID-19 Vaccine

Catalent Signs Agreement with Johnson & Johnson to be U.S. Manufacturing Partner for Lead COVID-19 Vaccine Candidate

Catalent

PR-M04-20-NI-044-1583Apr 30, 2020
Catalent
M&A

Catalent Completes Acquisition of MaSTherCell

Catalent

PR-M02-20-NI-014Feb 13, 2020
Catalent
M&A

Catalent Acquires Orgenesis' Cell Therapy Unit

Catalent

PR-M01-20-NI-046Feb 03, 2020
Building Upon an Integrated Biologics Offering
Integration

Building Upon an Integrated Biologics Offering

Catalent

PTV-M08-19-BIO-005Aug 12, 2019
Catalent
Strategic Relationship

IVERIC Bio Enters Into Strategic Manufacturing Relationship With Catalent’s Paragon Gene Therapy For Orphan Inherited Retinal Diseases

Catalent

PR-M06-19-NI-034Jun 20, 2019
Oral Solid Dose Manufacturing for Customers Now and into the Future
OSD

Oral Solid Dose Manufacturing for Customers Now and into the Future

Michael J. Valazza

Catalent

PAP-Q2-2019-CL-010May 24, 2019
Catalent
M&A

Catalent Completes Acquisition Of Gene Therapy Leader Paragon Bioservices, Inc. For $1.2 Billion

Catalent

PR-M05-19-NI-071May 24, 2019
Catalent
Acquisition

Catalent Completes Tender Offer for All Outstanding Shares of Juniper Pharmaceuticals, Inc.

Catalent

PR-M09-18-NI-028Sep 11, 2018
Catalent
Acquisition

Catalent Signs Agreement to Acquire Juniper Pharmaceuticals, Inc.

Catalent

PR-M07-18-NI-011Jul 05, 2018
Catalent
Expanded Capacity

Catalent Completes $4.6 Million Expansion at Singapore Clinical Supply Facility

Catalent

PR-M03-18-NI-008Mar 02, 2018
Catalent
Appointment

Catalent Announces Changes to its Board of Directors

Catalent

PR-M02-18-NI-84Feb 22, 2018
1 / 2